| |
|
|
|
|
|
Combination Steroid Anti-Biotic
|
Company:
Date:
April 24, 2009
|
|
|
|
|
|
|
|
|
|
Combination Steroid Anti-Biotic
|
Company:
Date:
April 24, 2009
|
|
|
|
|
|
|
|
|
|
Combination Steroid Anti-Biotic
|
Company:
Date:
April 24, 2009
|
|
|
|
|
|
|
|
|
|
NEVANAC® suspension (nepafenac ophthalmic suspension 0.1) treats eye pain and inflammation resulting from cataract surgery.
Do not wear contact lenses while using NEVANAC® suspension. Patients should not touch the bottle tip to any surface to avoid the risk of contamination.
This product should not be taken by patients with a sensitivity or allergy to its ingredients. Safety and efficacy have not been determined in children under age 10. Caution should be used when administering this drug to pregnant or nursing women. This drug should not be used in late pregnancy. The most common side effects
|
Company:
Date:
May 31, 2009
|
|
|
|
|
|
|
|
|
|
RESTASIS® ophthalmic emulsion is the first, and currently the only, prescription eye drop that helps to increase your eyes' natural ability to produce tears which may be suppressed by inflammation due to chronic dry eye. RESTASIS® ophthalmic emulsion did not increase tear production in patients using topical steroid drops or tear duct plugs. Artificial tears provide temporary relief of dry eye symptoms by putting water and lubricants on the surface of the eye. RESTASIS®, approved by the U.S. Food and Drug Administration in 2002, is currently the only prescription eye drop believed to address a
|
Company:
Date:
June 22, 2009
|
|
|
|
|
|
|
|
|
|
XIBROM™ophthalmic solution is indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction.
Clinical studies in patients following cataract surgery demonstrated:
Effectiveness
Significant reduction of ocular inflammation and pain with twice-daily dosing1
Comfort
Minimal incidence of burning or stinging reported in clinical trials (1.4)1
Safety
Few adverse events reported in clinical trials compared with placebo1
Lower preservative concentration (BAK) than currently available NSAIDs2-4
Clinical practice experience:
|
Company:
Date:
May 31, 2009
|
|
|
|
|